MX356111B - Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. - Google Patents

Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.

Info

Publication number
MX356111B
MX356111B MX2014009876A MX2014009876A MX356111B MX 356111 B MX356111 B MX 356111B MX 2014009876 A MX2014009876 A MX 2014009876A MX 2014009876 A MX2014009876 A MX 2014009876A MX 356111 B MX356111 B MX 356111B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
immediate release
abuse deterrent
deterrent pharmaceutical
molecular weight
Prior art date
Application number
MX2014009876A
Other languages
English (en)
Other versions
MX2014009876A (es
Inventor
N Raman Siva
Han Park Jae
A Diezi Thomas
J Herman Clifford
K Battu Sunil
A Burge Eric
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2014009876A publication Critical patent/MX2014009876A/es
Publication of MX356111B publication Critical patent/MX356111B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona composiciones farmacéuticas y procesos para preparar composiciones farmacéuticas en forma de dosis sólida que proporcionan liberación inmediata de los principios activos y tienen propiedades disuasorias de abuso. Las composiciones farmacéuticas proporcionadas en la presente comprende al menos un principio farmacéuticamente activo, al menos un polímero hidrófilo de bajo peso molecular, al menos un polímero hidrófilo de alto peso molecular, y un sistema efervescente.
MX2014009876A 2012-04-18 2013-04-18 Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. MX356111B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625926P 2012-04-18 2012-04-18
US201361792478P 2013-03-15 2013-03-15
PCT/US2013/037056 WO2013158814A1 (en) 2012-04-18 2013-04-18 Immediate release, abuse deterrent pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2014009876A MX2014009876A (es) 2014-11-13
MX356111B true MX356111B (es) 2018-05-15

Family

ID=48227563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009876A MX356111B (es) 2012-04-18 2013-04-18 Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.

Country Status (10)

Country Link
US (4) US9993422B2 (es)
EP (1) EP2838516B1 (es)
JP (1) JP6067100B2 (es)
BR (1) BR112014024382B1 (es)
CA (1) CA2864738C (es)
ES (1) ES2699806T3 (es)
IL (1) IL234997B (es)
MX (1) MX356111B (es)
PL (1) PL2838516T3 (es)
WO (1) WO2013158814A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
JP2019504072A (ja) * 2016-02-08 2019-02-14 スペックジーエックス エルエルシー 徐放性及び濫用抑止特性を有するグルコマンナン含有医薬組成物
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
ES3018268T3 (en) 2017-07-20 2025-05-14 Centrexion Therapeutics Corp Compositions and their use for treatment of pain using capsaicin
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ABUSE-PROOF IMMEDIATE RELEASE CAPSULE DOSAGE FORMS
EP4021423A4 (en) * 2019-08-27 2023-11-08 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
KR102603701B1 (ko) * 2020-12-04 2023-11-17 한국생산기술연구원 팽창성 창상피복재 및 이의 제조방법

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
JPS537495B2 (es) 1973-05-21 1978-03-18
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4678661A (en) 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
JPH0747532B2 (ja) 1985-10-16 1995-05-24 花王株式会社 錠剤の製造方法
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
DE69905380T2 (de) 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6660302B1 (en) 2000-09-06 2003-12-09 Chr. Hansen, Inc. Dry-powder film coating composition and method of preparation
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
WO2003032954A1 (en) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040005359A1 (en) 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
EP1658054B1 (de) 2003-08-06 2007-06-27 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US20050245557A1 (en) 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
AU2013206525B2 (en) 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
CN101484142B (zh) 2006-03-24 2013-06-05 奥克思利尤姆国际控股公司 包含对碱性不稳定的药物的稳定组合物
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2300188B1 (es) 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080075768A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
NZ577560A (en) 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
KR101521989B1 (ko) 2007-03-02 2015-05-28 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
JP5550546B2 (ja) * 2007-04-13 2014-07-16 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド 経口セファロタキシン剤形
EP2161021B1 (en) 2007-06-07 2017-03-08 Sato Pharmaceutical Co. Ltd. Medicinal film preparation with rapidly dissolving property and flexibility
US20090124650A1 (en) 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
EP2277861A4 (en) 2008-05-07 2012-05-02 Dainippon Sumitomo Pharma Co CYCLIC AMIN-1-CARBOXYLIC ACID EST DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREWITH
BRPI0913724B8 (pt) 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
JP5017516B2 (ja) 2009-11-13 2012-09-05 株式会社ホットアルバム炭酸泉タブレット 錠剤の製造方法
WO2011066980A2 (en) 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
US20120321716A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for preventing abuse of solid dosage forms
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
US20150224097A1 (en) 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
EP2838536B1 (en) 2012-04-18 2017-08-09 Mallinckrodt LLC Immediate release pharmaceutical compositions with abuse deterrent properties
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
CA2901802C (en) 2013-03-15 2021-03-02 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides

Also Published As

Publication number Publication date
PL2838516T3 (pl) 2019-05-31
BR112014024382B1 (pt) 2022-08-09
EP2838516B1 (en) 2018-10-17
JP2015514775A (ja) 2015-05-21
US20180256493A1 (en) 2018-09-13
IL234997B (en) 2019-02-28
EP2838516A1 (en) 2015-02-25
JP6067100B2 (ja) 2017-01-25
ES2699806T3 (es) 2019-02-12
US20180008532A1 (en) 2018-01-11
WO2013158814A1 (en) 2013-10-24
CA2864738A1 (en) 2013-10-24
BR112014024382A2 (es) 2017-06-20
CA2864738C (en) 2017-07-18
US20180280289A1 (en) 2018-10-04
WO2013158814A8 (en) 2014-06-19
MX2014009876A (es) 2014-11-13
US9993422B2 (en) 2018-06-12
US20130280177A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
MX2015012060A (es) Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional.
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
EP4670712A3 (en) Multi-layer nicotine-containing pharmaceutical composition
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
WO2012174158A3 (en) Administration of benzodiazepine
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
HK1213779A1 (zh) 用於立即和延长释放的组合物
BR112013017750A2 (pt) nanocápsulas com envoltório polimérico
WO2013003827A3 (en) Macrogol 15 hydroxystearate formulations
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
HK1203815A1 (en) Pharmaceutical compositions and methods for their preparation
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2016040814A3 (en) Disulfide polymers and methods of use
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2013170086A3 (en) Formulations for the delivery of active ingredients
MX371297B (es) Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SPECGX LLC

FG Grant or registration